ONWARD Medical

“They want to regain their hand function. So, it was really important to us to be able to provide something and partner with a company like ONWARD Medical that knew how to get this technology into the markets. Right now, it's available in 130 clinics across the US. It's also approved for home use. And what we're really excited about is that it's now going to be available at the VAs.”

Maggie Goldberg, President and CEO of the Christopher & Dana Reeve Foundation joined Ryan Schmelz on LiveNOW from FOX this weekend to talk about the adoption of our technology and what it means for the spinal cord injury community.

The conversation explored advances in transcutaneous spinal cord stimulation to improve hand strength and sensation following spinal cord injury, such as the ARC-EX® System. It delved into how ARC-EX can help Veterans living with spinal cord injury achieve greater independence.

If you missed the live segment, tune in below as Maggie discusses ARC-EX, the first US FDA-cleared technology indicated to improve hand sensation and strength after #SCI.

youtube.com/watch?v=hcXtNq…

#SpinalCordInjury #EmpoweringMovement #Medtech #ARCEX

ARC-EX Indication for Use: The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, nonprogressive neurological deficits resulting from an incomplete spinal cord injury (C2-C8 inclusive). The ARC-EX System is intended to be operated in medical centers by rehabilitation professionals and at home by patients and persons providing assistance to patients, as needed

We are delighted to announce the appointment of Fouad Azzam to our Board of Directors. Fouad is a Partner at EQT Sciences and brings extensive experience investing in and supporting fast-growing medical technology and life sciences companies.

“ONWARD combines breakthrough science, a high potential business opportunity, and a clear path to make a meaningful impact for people living with paralysis,” said Fouad. “I look forward to supporting the ONWARD team as they expand access to the ARC-EX System and advance the broader pipeline, which includes groundbreaking implantable spinal cord stimulation and brain-computer interface technologies.”

Read the full press release: ir.onwd.com/static-files/9…

#Medtech #BCI #EmpoweringMovement

We‘re looking forward to the @ Spinal Cord Injury Patient-Focused Drug Development (PFDD) Meeting. This free, virtual event gives people living with spinal cord injuries and their care partners an opportunity to share their perspectives with health authorities, researchers, and industry. Participants can also contribute to a public “Voice of the Patient” report that will inform US FDA decision-making and research priorities.

ONWARD Medical is committed to pioneering therapies to restore movement, function, and independence in people with SCI and other movement disabilities. We firmly believe that sharing the experiences of the SCI community will help shape the future of therapy development.

🖋️ Register now and join the conversation: scipfdd.org/register

We were pleased to see ONWARD Medical featured among BCI innovators in the @FT ’s latest article on the fast-moving field of brain-computer interfaces. Thank you to @clivecookson and Michael Peel for highlighting our work.

The investigational ARC-BCI® System is one of the world’s most advanced platforms pairing a brain-computer interface with an implantable spinal cord stimulation system. To date, seven study participants have received ARC-BCI Therapy, designed to enable thought-driven movement of their own paralyzed limbs. We continue to learn from this groundbreaking clinical feasibility research and leverage our unique understanding of spinal cord stimulation to restore movement after paralysis.

Read the full story: ft.com/content/d76506…

ARC-BCI is investigational and not available for commercial use.

Today, we announced our results for the first half of 2026, reporting strong revenue growth and continued progress across the ARC Therapy pipeline. 159 ARC-EX® Systems were sold or supplied via paid evaluation, and we continue to make steady progress in the development of our investigational ARC-IM® and ARC-BCI® platforms. With growing commercial momentum and a strengthened balance sheet, we are well positioned to pursue our mission to restore movement, function, and independence in people with spinal cord injuries and other movement disabilities.

Read the full press release: ir.onwd.com/static-files/d…

ARC-EX Indication for Use: The ARC-EX System is intended to deliver programmed, transcutaneous electrical spinal cord stimulation in conjunction with functional task practice in the clinic and with take-home exercises in the home to improve hand sensation and strength in individuals between 18 and 75 years old that present with a chronic, nonprogressive neurological deficits resulting from an incomplete spinal cord injury (C2-C8 inclusive). The ARC-EX System is intended to be operated in medical centers by rehabilitation professionals and at home by patients and persons providing assistance to patients, as needed.

Other Investigational Products: All other ONWARD Medical devices and therapies, including ARC-IM and ARC-BCI, are investigational and not available for commercial use